The treatment results of patients with hepatocellular carcinoma

Introduction. Hepatocellular carcinoma (HCC) is a primary tumor, accounting for 80–85 % of all malignant liver tumors. According to world statistics, the incidence of HCC ranks 6th, and mortality – 3rd. The prevalence of the disease in the Russian Federation has increased by 8 % over the past 5 years and is 4–5 cases per 100 thousand population per year, while stages III–IV account for about 80 %. Treatment of this pathology is a complex task and should take into account many factors. The aim of the study was to analyze the treatment results of patients with HCC for the period from 2008 to 2024.
Materials and methods of research. A retrospective analysis of the treatment of 197 patients with hepatocellular carcinoma (HCC) was performed, the average age was 61.3 ± 8.5 years, men – 140 (71 %), women – 57 (29 %). Liver resection was performed in 82 patients, locoregional techniques were performed in 119 patients.
Treatment results. The average duration of the operation was 179 ± 28,3 min; the average bed-day was 11 ± 3 days; the survival rate was 83 % at one year, 75 % at two years, 50 % at three years, and 32 % at five years. The time of LRT procedures were as follows: RFA –12 ± 2,8 min, MVA – 7 ± 2,3 min, LA – 6 min. The survival rate after RFA of liver tumors was 81% at one year, 62 % at two years, 39 % at three years, and 28 % at five years. When performing MVA of liver tumors, the survival rate was 83 % at one year, 67 % at two years, 42 % at three years, and 31 % at five years.
Conclusion. An integrated approach to the treatment of patients with primary liver cancer allows us to determine the optimal tactics, which increases the effectiveness of treatment, increases life expectancy and improves its quality, and makes it possible to use local methods in somatically burdened patients.

1. Breder V.V. et al. Malignant tumors of the liver and biliary system. Malignant tumors, 2024, № 3s2-1, рр. 358–403. (In Russ.) https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-17

2. Ziaei Y. et al. Liver resection for hepatocellular and fibrolamellar carcinoma in a South African tertiary referral centre–an observational cohort analysis. South African Journal of Surgery, 2024, № 2, pp. 102–107. https://doi.org/10.36303/SAJS.00198

3. Papaconstantinou D., Tsilimigras D., Pawlik T. Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment. Journal of hepatocellular carcinoma, 2022, pp. 947–957. https://doi.org/10.2147/JHC.S342266

4. Kaprin AD, Starinskii VV, Petrova GV. The state of oncological care for the population of Russia in 2022. Moscow: P.A. Herzen Moscow Oncology Research Institute - branch of the Federal State Budgetary Institution “NMITs of Radiology” of the Ministry of Health of the Russian Federation, 2023. (In Russ.)

5. Kovalenko N.V. et al. Review of global trends in interventional X-ray endovascular treatment of patients with malignant neoplasms and metastatic liver lesions. Surgery, 2023, № 9, pp. 72–78. https://doi.org/10.17116/hirurgia202309172 (In Russ.)

6. Kinsey E., Lee H. Management of hepatocellular carcinoma in 2024: The multidisciplinary paradigm in an evolving treatment landscape. Cancers, 2024, № 3, pp. 666. https://doi.org/10.3390/cancers16030666

7. Hong S. et al. Impact of tumor size on hepatectomy outcomes in hepatocellular carcinoma: a nationwide propensity score matching analysis. Annals of Surgical Treatment and Research, 2022, № 4, pp. 193–204. https://doi.org/10.4174/astr.2022.102.4.193

8. Ivanics T. et al. Dynamic risk profiling of HCC recurrence after curative intent liver resection. Hepatology, 2022, № 5, pp. 1291–1301. https://doi.org/10.1002/hep.32411

9. Sugawara Y., Hibi T. Surgical treatment of hepatocellular carcinoma. BioScience Trends, 2021, № 3, pp. 138-141. https://doi.org/10.5582/bst.2021.01094

10. Novruzbekov M. S., Olisov O. D. On the issue of liver transplantation in patients with hepatocellular carcinoma (a brief review of the literature). Malignant tumors, 2016, № 1, pp 36–39. (In Russ.) https://doi.org/10.18027/2224-5057-2016-4s1-36-39

11. Olisov O. D. et al. The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation. Transplantology, 2022, № 3, pp. 292–300. (In Russ.) https://doi.org/10.23873/2074-0506-2022-14-3-292-300

12. Volk M., Vijan S., Marrero J. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. American Journal of Transplantation, 2008, № 4, pp. 839–846. https://doi.org/10.1111/j.1600-6143.2007.02138.x

13. Shiina S. et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Official journal of the American College of Gastroenterology ACG, 2012. № 4, pp. 569–577. https://doi.org/10.1038/ajg.2011.425

14. Yamada S. et al. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Annals of surgical oncology, 2014, № 21, pp. 436–442. https://doi.org/10.1245/s10434-014-3575-z

15. Wang B. et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiologica, 2008, № 5, pp. 523–529. https://doi.org/10.1080/028418508019588

16. Sergio A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Official journal of the American College of Gastroenterolog ACG, 2008, № 4, pp. 914–921.

17. Zhang Y. et al. Comparison of the Efficacy and Safety of Transarterial Chemoembolization Plus Microwave Ablation versus Surgical Resection in Patients with Solitary Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Journal of Hepatocellular Carcinoma, 2022, pp. 1309-1321. https://doi.org/10.2147/JHC.S386264\

18. Efimov D. U. et al. Oncological feasibility of liver transplantation in hepatocellular carcinoma. Annals of surgical hepatology, 2020, № 2, pp. 77–85. (In Russ.) https://doi.org/10.16931/1995-5464.2020277-85

19. Lindemann J., Yu J., Doyle M. New horizons in liver transplantation for hepatocellular carcinoma. South African Journal of Surgery, 2024, № 2, pp. 95–101. https://doi.org/10.36303/SAJS.00395